ArticleBlood advances2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 202 citations in OpenAlex.
- Retrospective analysis of primary extranodal unicentric Castleman disease: a systematic review.Frontiers in medicine · 2026Pooled it
- The clinical picture of Castleman disease: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Unicentric form of Castleman´s disease, pitfalls of diagnosis and surgical treatment.Frontiers in oncology · 2023Pooled it
- Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.Renal failure · 2026Review
- Unicentric hyaline-vascular Castleman disease of the jejunal mesentery mimicking a gastrointestinal stromal tumor or neuroendocrine tumor: a case report.International journal of surgery case reports · 2026Article
- Unicentric Castleman disease presenting as hyperenhancing mediastinal mass: A case series diagnosed by linear endobronchial ultrasound guided mediastinal nodal biopsy.Lung India : official organ of Indian Chest Society · 2026Article
- [Clinical diagnosis and treatment of four cases of Castleman disease in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Systemic lupus erythematosus combined with Castleman disease: a case report.Wiener klinische Wochenschrift · 2026Article
- Definitive Radiotherapy for Unresectable Unicentric Mediastinal Castleman Disease: A Case Report.Cureus · 2026Article
- Article
- Clinical features and therapeutic outcomes in pediatric patients with Castleman's disease: a retrospective cohort analysis.European journal of pediatrics · 2026Article
- Castleman disease arising from the pleura: a case report and literature review.Journal of cancer research and clinical oncology · 2026Review
- Unicentric Pulmonary Castleman Disease Mimicking Lung Cancer: A Case Report.Respirology case reports · 2026Article
- Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.Blood advances · 2026Article
- Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.American journal of clinical pathology · 2026Review
- Unicentric Castleman disease with paraneoplastic pemphigus and follicular dendritic cell sarcoma: A case report.Oncology letters · 2026Article
- Snapshot Look at Castleman Disease.Journal of cellular and molecular medicine · 2026Review
- Mesenteric Castleman disease: Two case reports and review of literature.World journal of gastrointestinal surgery · 2026Article
- Diagnostic delay and histopathological subtyping challenges in idiopathic multicentric Castleman disease, not otherwise specified: a case report of a three-hospital odyssey.Frontiers in medicine · 2026Article
- Case report: A rare case of retroperitoneal mixed type unicentric Castleman disease.Frontiers in oncology · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 18 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)-associated MCD, POEMS-associated MCD, and HHV-8-/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti-interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.